CONTENTS
· Scientific Agenda
· Continuing Medical
  Education
· Who Should Attend?
· Objectives
· Registration
· General Information
· Hotel Accomodations
· Organizer

Jan M. Bruder, MD
University of Texas Health Science
Center at San Antonio
San Antonio, Texas

Michael A. Carducci, MD
Johns Hopkins University
Baltimore, Maryland

Michael S. Cookson, MD
Vanderbilt University Medical Center
Nashville, Tennessee

E. David Crawford, MD
University of Colorado Health
Sciences Center
Denver, Colorado

Robert Dreicer, MD, FACP
Cleveland Clinic Foundation
Cleveland, Ohio

Inderbir S. Gill, MD, MCh
Cleveland Clinic Foundation
Cleveland, Ohio

Daniel P. Petrylak, MD
Columbia University Medical Center
New York, New York

Derek Raghavan, MD, PhD, FACP, FRACP
Cleveland Clinic Foundation
Cleveland, Ohio

Mack Roach, III, MD
University of California San Francisco
UCSF Comprehensive Cancer Center
San Francisco, California

Mark A. Rubin, MD
Brigham and Women's Hospital
Boston, Massachusetts

Heiko Schöder, MD
Memorial Sloan-Kettering Cancer Center
New York, New York

Eric J. Small, MD
University of California, San Francisco
San Francisco, California

Ian M. Thompson, Jr., MD
University of Texas Health Science
Center at San Antonio
San Antonio, Texas

Nicholas T. Vogelzang, MD, PhD
Nevada Cancer Institute
Las Vegas, Nevada

Thursday, September 21 2006

8:00 am
Welcome and introduction
Eric J. Small, MD and Ian M. Thompson, Jr., MD

Session I: Screening, imaging and diagnosis

8:05 am
PSA: Integration with other markers of risk
Ian M. Thompson, Jr., MD

8:30 am
Imaging guidance in treatment and follow-up
Heiko Schöder, MD

8:55 am
New prognostic indicators
Mark A. Rubin, MD

9:20 am
Panel discussion

Session II: Surgical advances

9:30 am
Laparoscopy/robotics
Inderbir S. Gill, MD, MCh

10:00 am
Surgical pathways
Michael S. Cookson, MD

10:25 am
Panel discussion

10:35 am
Break

Session III: Early disease

10:55 am
When watchful waiting is a good or a bad choice
Ian M. Thompson, Jr., MD

11:20 am
State-of-the-art radiotherapy
Mack Roach, III, MD

11:45 am
The emergence of chemotherapy for early stage disease
Robert Dreicer, MD, FACP

12:10 pm
Coordination of the urologist and oncologist for early disease: Maximizing treatment outcomes
Michael A. Carducci, MD

12:40 pm
Panel discussion

1:00 pm
Lunch

Session IV: Advanced disease

2:00 pm
T3-4 disease: Is there a role for surgery?
E. David Crawford, MD

2:25 pm
Androgen deprivation therapy: When and how much?
Eric J. Small

2:50 pm
Managing the complications of androgen deprivation
Jan M. Bruder, MD

3:15 pm
Break

3:35 pm
When hormone resistant prostate cancer isn't hormone resistant
Eric J. Small, MD

4:05 pm
Chemotherapy options for hormone-refractory patients and when to use them
Daniel P. Petrylak, MD

4:35 pm
Management of recurrent disease
Nicholas J. Vogelzang, MD, PhD

5:05 pm
Coordination of the urologist and oncologist for advanced disease: Maximizing treatment
Robert Dreicer, MD, FACP

5:35 pm
Panel discussion

5:45 pm
Adjourn

Friday, September 22, 2006

8:00 am
Welcome
Eric J. Small, MD

Session IV: Advanced disease (cont.)

8:05 am
Is PSA a ‘prime time’ tool for management of advanced disease and disease recurrence?
Derek Raghavan, MD, PhD, FACP, FRACP

8:55 am
Panel discussion

Session V: Emerging treatment options

9:05 am
Immunotherapy
Eric J. Small, MD

9:40 am
New cytotoxic agents on the horizon
Robert Dreicer, MD

10:05 am
A review of late phase chemotherapy trials
Michael A. Carducci, MD

10:30 am
Panel discussions

10:40 am
Break

Session VI: Case discussions: Incorporating lessons learned into practice
Moderators: Eric J. Small, MD and Ian M. Thompson, Jr., MD
Panel: E. David Crawford, MD, Mack Roach, III, MD, Nicholas Vogelzang, MD, PhD

11:00 am

• Case 1 - Very high-risk young patient withT1c disease, PSA 8, all cores, Gleason 4+4
• Case 2 - T3c, Gleason 4+4, detectable PSA, XRT, rising PSA. What next?
• Case 3 - M1, s/p hormones, rising PSA, asymptomatic
• Case 4 - T3, Gleason 3+4, 79 year old male with osteoporosis

12:00 pm
Chair summary and adjourn

Imedex^®, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Imedex, Inc. designates this educational activity for a maximum of 11.50 category 1 credits toward the AMA Physician's Recognition Award. Each physician should claim only those credits that he/she actually spent in the activity.

This meeting is designed for urologists, medical oncologists, radiation oncologists, and other healthcare administrators with an interest in the management of patients with prostate cancer. No specialized knowledge is required for participation in this course other than a basic knowledge of cancer.

Click here to register for this program

After successful participation in this congress, attendees should be able to:

• Understand the latest developments in surgery, radiation therapy, and systemic therapy for prostate cancer
• Identify methods to facilitate coordination between urologists and oncologists toward optimal management of prostate cancer patients
• Comment on promising future strategies for the management of prostate cancer
• List the latest and most important prognostic and predictive factors in prostate cancer
• Select the most appropriate techniques for initial evaluation and follow-up of prostate cancer patients
• Assess efficacy of prostate cancer treatment paradigms through case studies

Click here to register for this program

Registration Fees
 
Regular: $295 (If payment is received by September 14, 2006)

Full: $395 (If payment is received after September 14, 2006)

Nurses/Residents/Students*: $75 (*proof of eligibility mustaccompany registration)
Group Discount: — $50 Physician registrants only

To Register: You may register online or call Imedex at +1 (770) 751 7332. Registration confirmations will be issued before the congress.

Registration confirmations will be issued before the meeting. To qualify for special registration fees, registration and full payment must be received by Imedex by the dates specified.

Group Discounts: Two or more physicians from the same institute or practice each receive a $50 discount off the published registration fees, provided all registration forms and payments are received together. Only one discount will apply per physician. Discounts do not apply to the Nurses/Residents/Students fee.

Payment: Registration payments can be remitted by credit card, check, or wire transfer. Checks should be payable to Imedex.

To pay via wire transfer, you must add $25 to each transaction to cover bank charges. Include the full name of the attendee and the name of the conference: 256 – US Prostate. Attendee is not registered until full payment is received.

Registration Fee Inclusions: Registration fees include admittance to scientific sessions, conference materials and all functions as specified in the program.

Cancellation: For registration fees to be refunded, written notice of cancellation must be received at Imedex by September 14, 2006. The amount of registration fees remitted, minus a $75 administrative charge, will be refunded after the conference. Substitutions are accepted with written notification. After September 14, 2006, no refunds will be made.

Imedex does not accept responsibility for covering travel, accommodation or any other costs incurred by registrants in the rare event that this program should be cancelled for any reason. Every effort will be made to give reasonable notice in the event of cancellation. The event program content is subject to change without notice.

Registration Fee Inclusions: Registration fees include admittance to scientific sessions, congress materials and all functions as specified in the program.

CONFERENCE LOCATION
The Fairmont Chicago
200 North Columbus Drive
Chicago, Illinois 60601
Tel.: +1 (312) 565 8000
Fax: +1 (312) 856 1032

Reservations:
+1 (312) 565 6698
+1 (800) 257 7544
Web: www.fairmont.com/chicago

Registration Hours
The Registration and Information Desk will be staffed:

Thursday, September 21, 2006: 7:00 am – 6:00 pm

Friday, September 22, 2006: 7:00 am – 12:00 pm

Discounted Airfares
Contact the conference travel agency for assistance with your travel needs. Age of Travel can also accommodate pre- and post-conference extensions.
Age of Travel
Tel.: +1 (800) 523 4954 or +1 (404) 591 7120
Email: Imedex@ageoftravel.com

The Fairmont Chicago
200 North Columbus Drive
Chicago, Illinois 60601
Tel.: +1 (312) 565 8000
Fax: +1 (312) 856 1032

Reservations:
+1 (312) 565 6698
+1 (800) 257 7544
Web: www.fairmont.com/chicago

Rising gracefully above Millennium Park and Chicago’s impressive lakefront, The Fairmont Chicago is located conveniently in the heart of downtown Chicago, near major cultural attractions, Navy Pier, the city’s business and financial district and the world renowned shopping along the Magnificent Mile.

For the convenience of attendees, a limited number of rooms have been reserved until September 6, 2006 at a rate of $275.00, Single or Double Occupancy, plus tax, currently at 15.4%. This rate is not guaranteed outside the conference dates.

To make reservations, please contact The Fairmont Chicago’s Reservations Department at +1 (312) 565 6698 or visit the hotel’s website at www.fairmont.com/chicago. To receive the group rate, callers must identify themselves as being with the “Perspectives in Prostate Cancer” group. Internet users must enter the meeting promotional code: GRMED1.

Reservation requests received after September 6, 2006 may not be guaranteed the group rate.

          4325 Alexander Drive
          Alpharetta, GA 30022-3740 USA
          Tel.: +1 (770) 751 7332
          Fax: +1 (770) 751 7334
          Email: meetings@imedex.com
          Web: www.imedex.com